CDC/ACIP [to 21 April 2018]

http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for April 19, 2018
Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended the use of HEPLISAV-B (HepB-CpG) vaccine, a 2-dose series hepatitis B vaccine for use in people 18 years of age or over. Hepatitis B vaccination is the primary means of preventing infections and complications caused by hepatitis B virus. Prior to making this recommendation, the ACIP Hepatitis Vaccines Work Group conducted a systematic review of the existing evidence to determine that the benefits of protection with two doses administered over one month make the HEPLISAV-B (HepB-CpG) vaccine an important option for prevention of hepatitis B in at-risk persons.